Breaking News: Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label | Financial Buzz

Breaking News: Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. applauds the Biden Administration’s Acceleration of Whole-of-Government Effort to Prevent, Detect, and Treat Long COVID announced on April 5th, 2022. The Company believes that the tremendous burden of Long COVID, recently estimated to affect over 22 million Americans and leading directly to over 7 million Americans with disabling Long COVID with a total personal financial burden of over $380 billion dollars, must be met with an overwhelming investment in new therapies for Long COVID with a government focus akin to Operation Warp Speed.

Concurrent with this announcement, the Company announced that the US FDA recently granted a new Certificate of Free Sale for its proprietary 3CL protease inhibitor, immune support dietary supplement Tollovid® that allows for both acute dosing for immune support (12 pills per day for 5 days) and chronic daily dosing for maintenance (2 pills per day) on the same label. A recent case study was reported by Dr. John Mabayoje outlining the potential benefit of Tollovid in the treatment of debilitating Long COVID in which a 49-year old female Long COVID sufferer who was chronically testing COVID positive by PCR for over 3 months from initial COVID diagnosis and experienced Long COVID symptoms including low energy, excessive somnolence, easy fatigability, myalgia, and headaches. This patient saw complete resolution of all Long COVID symptoms following the initial 5-day dosing regimen of Tollovid, immediately afterwards tested negative by COVID PCR, and was able to return to her job as a flight attendant immediately afterwards while staying healthy for four months to date following Tollovid intervention. The Company intends to conduct further research in this area with Tollovid, and is currently working to turn Tollovid into an OTC drug. Tollovid is currently not approved to diagnose, treat, prevent or cure any disease, including COVID or Long COVID. 

Additionally the Company is developing the separate, but related, therapeutic drug candidate Tollovir™ for the treatment of hospitalized COVID-19 (severe/critical) that recently completed a Phase 2a clinical study at Shaare Zedek Medical Center in Jerusalem, Israel in which Tollovir + standard of care (SOC) showed superiority vs. SOC alone. In the Phase 2a study the Tollovir treatment arm showed 40% reduction in time in the hospital (10.6 days vs. 17.8 days), 100% reduction in death while on therapy (0% vs. 22%) and 50% benefit in patients achieving clinical improvement a measured by the National Emergency Warning System 2 rating scale, also known as NEWS2, (100% vs. 67%). Tollovir is currently available by compassionate use at Shaare Zedek Medical Center for patients, and the Company is preparing regulatory submissions in certain jurisdictions for Emergency Use Authorization (EUA) outside the United States and preparing for a Phase 2b/3 trial to support US FDA and other regulatory government submissions.

“It is clear that the scale of the COVID pandemic has dramatically raised the stakes for chronic disease in the United States,” said Gerald E. Commissiong, President & CEO of Todos Medical, the parent company of 3CL Pharma. “At its peak, it was estimated that during the Omicron wave over 3 million cases were recorded per day in the United States. Recent estimates suggest that roughly 10% of those who recover from COVID will suffer from Long COVID, and furthermore that the risk factor for diabetes in those who were diagnosed with COVID within the last 12 months were at a 2% higher likelihood of developing diabetes. This is a national and international emergency at an unprecedented scale that could have reverberating impacts for decades to come for societies that allow COVID to spread widely. We must immediately marshal the resources necessary to bring to market all the different effective therapies that could have a benefit in the treatment of Long COVID and initiate studies to address this major public health issue. Chronic disease pre-COVID represented an almost $1.2 trillion market, and Long COVID is likely to dramatically exacerbate this problem. As such, we stand with the Biden Administration to underscore the urgent need for new therapies to treat Long COVID.”

About Tollovid® 

Tollovid is a dietary supplement product made from natural ingredients that help support and maintain healthy immune function and also has potent 3CL protease inhibition properties based upon in vitro functional assays that show strong inhibition of 3CL protease activity. Tollovid’s 3CL protease IC50 binding affinity is at least ten times as strong as Ivermectin’s published 3CL protease IC50 binding affinity. Tollovid binds to the active site (receptor binding domain) of the 3CL protease. Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support. 

About Tollovir®

Tollovir® is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity. Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19. Todos has licensed rights for Tollovir to T-Cell Protect Hellas S.A. for the Greek market.

About Todos Medical Ltd.

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers’ life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.

Sponsored Content Release. Click for Full Disclosure

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For todos medical ltd. video production, filming editing, news reporting, financial and corporate news dissemination, has signed a five-month agreement with the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. has agreed to fifteen million restricted shares, will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: